Equities research analysts expect Myovant Sciences Ltd (NYSE:MYOV) to announce earnings per share of ($0.81) for the current quarter, Zacks reports. Zero analysts have made estimates for Myovant Sciences’ earnings, with the highest EPS estimate coming in at ($0.77) and the lowest estimate coming in at ($0.84). Myovant Sciences reported earnings per share of ($1.04) in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.1%. The business is expected to announce its next earnings results on Thursday, February 6th.
On average, analysts expect that Myovant Sciences will report full year earnings of ($3.29) per share for the current fiscal year, with EPS estimates ranging from ($3.35) to ($3.18). For the next financial year, analysts forecast that the business will report earnings of ($3.16) per share, with EPS estimates ranging from ($3.72) to ($2.51). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Myovant Sciences.
Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.07).
In other Myovant Sciences news, major shareholder Sciences Ltd. Roivant acquired 3,500,000 shares of Myovant Sciences stock in a transaction that occurred on Monday, November 25th. The stock was acquired at an average price of $15.00 per share, with a total value of $52,500,000.00. Following the purchase, the insider now owns 44,509,411 shares in the company, valued at $667,641,165. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders purchased 3,876,099 shares of company stock valued at $58,656,406. 3.00% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of MYOV. Barclays PLC lifted its holdings in Myovant Sciences by 24.6% in the 3rd quarter. Barclays PLC now owns 11,317 shares of the company’s stock worth $59,000 after purchasing an additional 2,234 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Myovant Sciences by 46.3% during the third quarter. Tower Research Capital LLC TRC now owns 9,741 shares of the company’s stock worth $51,000 after purchasing an additional 3,083 shares during the period. Atria Investments LLC boosted its position in Myovant Sciences by 87.9% during the second quarter. Atria Investments LLC now owns 22,915 shares of the company’s stock worth $162,000 after purchasing an additional 10,720 shares during the period. Northern Trust Corp acquired a new position in Myovant Sciences during the second quarter valued at approximately $105,000. Finally, BlackRock Inc. grew its holdings in Myovant Sciences by 59.1% during the second quarter. BlackRock Inc. now owns 44,637 shares of the company’s stock valued at $404,000 after purchasing an additional 16,580 shares during the last quarter. 38.81% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:MYOV traded down $0.17 during midday trading on Friday, hitting $16.61. 2,183,809 shares of the stock were exchanged, compared to its average volume of 787,760. The company has a market capitalization of $1.67 billion, a PE ratio of -4.06 and a beta of 2.02. Myovant Sciences has a 52-week low of $4.14 and a 52-week high of $26.02. The company has a debt-to-equity ratio of 5.88, a quick ratio of 2.79 and a current ratio of 2.79. The business’s fifty day simple moving average is $9.18 and its two-hundred day simple moving average is $8.24.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Featured Article: Shanghai Stock Exchange Composite Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.